Recent News About Janssen Pharmaceuticals, Inc. View More
- State Court
HARRISBURG – The Superior Court of Pennsylvania has reinstated a Risperdal lawsuit which was thrown out after 11 days of trial proceedings in a Philadelphia court in December 2016 and said its original granting of nonsuit was improper.
Houston men sue in Philly as J&J faces more claims from Invokana users who say they were at higher risk for amputations
PHILADELPHIA – More lawsuits are alleging that Johnson & Johnson’s diabetes medication, Invokana, gave them an increased risk of suffering amputations – and that the company failed to warn them of that same risk.
PHILADELPHIA – A trio of new lawsuits joins others recently filed taking aim at Johnson & Johnson’s Invokana medication for Type 2 diabetes, claiming the company failed to warn its users that the medicine put them at increased risk for amputations they suffered as a result of taking the drug.
PHILADELPHIA – A Delaware County couple have launched legal action against Johnson & Johnson and its subsidiary Janssen Pharmaceuticals, claiming its Type 2 diabetes treatment medication Invokana failed to contain warnings regarding users being at increased risk for amputations.
PHILADELPHIA – A Philadelphia judge’s decree has paved the way for new trials in two Risperdal cases, in order to determine the applicability of punitive damages in those same actions.
Johnson & Johnson, Bayer seek dismissal of 12 Philadelphia Xarelto lawsuits, say fact sheets are missing
PHILADELPHIA – According to a recent filing, counsel for the manufacturers of blood thinner-drug Xarelto are looking to have the lawsuits of certain plaintiffs dismissed with prejudice, supposedly for not complying with filing guidelines.
PHILADELPHIA – A notable 2017 U.S. Supreme Court decision intended to limit the practice of forum-shopping has not deterred thousands of plaintiffs from filing pharmaceutical litigation in Philadelphia courts, recently-released statistics show.
Early returns haven't been positive for plaintiffs attorneys, so Xarelto liability theories have been mutating, defense says